Cell Biology in Kidney Cancer
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Microenvironment".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 4935
Special Issue Editors
Interests: kidney; urothelial
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the last fifteen years, a better understanding of the molecular mechanisms underlying neoplastic development and progression have led to a radical change in the therapy landscape of advanced renal cell carcinoma.
Renal cell carcinoma is a heterogeneous disease with several genetic and molecular alterations. Angiogenesis is a key player in the pathogenesis of this disease. In particular, the role of the mutations in the Von Hippel-Lindau tumor-suppressor gene, leading to an overexpression of the hypoxia-induced factors, is clearly defined.
The understanding of this biological landscape led to the development of therapies targeting VEGF and mTOR pathways. Three classes of targeted therapies with antiangiogenetic activity have received approval for advanced disease treatment: several tyrosine kinase inhibitors; a monoclonal antibody interfering with VEGF; and two mTOR inhibitors. These drugs have demonstrated impressive results in terms of objective response and progression-free survival.
Very recently, a deep improvement of the interplay between angiogenetic factors and immune cells led to a new revolution in the treatment landscape of this carcinoma. Combinations of immune-checkpoint inhibitors and immune-checkpoint inhibitors plus tyrosine kinase inhibitors have been shown to improve overall survival compared to tyrosine kinase inhibitor monotherapy, shifting the systemic treatment of this tumor from the "targeted therapy era" to the "golden age".
However, many questions remain to be explored. This Special Issue focuses on predictive biomarkers of response to available therapeutic agents, how to overcome the mechanisms of resistance, and the best therapy sequencing in daily clinical practice.
We look forward to your contributions.
Dr. Marcello Tucci
Dr. Consuelo Buttigliero
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
